Intellia Therapeutics Names Edward Dulac Finance Chief

Dow Jones06-26
 

By Chris Wack

 

Intellia Therapeutics said it has appointed Edward Dulac as executive vice president, finance chief and treasurer, effective July 22.

The clinical-stage gene editing company said Wednesday that Dulac will succeed Glenn Goddard, who will step down from his role effective June 30.

Intellia said Dulac most recently served as CFO of Fate Therapeutics.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

June 26, 2024 07:42 ET (11:42 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment